This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
4D-710 in Adult Patients with Cystic Fibrosis
-
University of Alabama Child Health Research Unit, Birmingham, Alabama, United States, 35233
University of California San Francisco, San Francisco, California, United States, 94143
National Jewish Health, Denver, Colorado, United States, 80206
University of Florida, Gainesville, Florida, United States, 32610
Northwestern Memorial Hospital, Chicago, Illinois, United States, 60611
University of Kansas Medical Center, Kansas City, Kansas, United States, 66160
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44146
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
4D Molecular Therapeutics,
Alan H. Cohen, MD, STUDY_DIRECTOR, 4D Molecular Therapeutics
2030-01